BRCA1 mutation + TMB-H
|
NSCLC
|
BRCA1 mutation + TMB-H
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
BRCA1 mutation + TMB-H
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation + TMB-H
|
Pancreatic Adenocarcinoma
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
BRCA1 mutation + TMB-H
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation + TMB-H
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|